IRadimed posts revenue gains in Q3

IRadimed reported revenue of $24.2 million for the third quarter of 2026, up 14% from the same period of 2025.

Net income for the quarter (end-September 30) was $6.5 million, up 17% from $5.6 million a year earlier. GAAP diluted earnings per share were $0.51, and non-GAAP diluted earnings per share were $0.55, both up from $0.43 and $0.47, respectively, in the same period last year.

The company’s board of directors also declared a quarterly cash dividend of $0.20 per share, payable November 27, to shareholders of record as of November 13.

For the fourth quarter, iRadimed expects revenue of $25 million to $26.5 million. For the full year, the company expects revenue of $91.6 million to $93.1 million.

IRadimed reported revenue of $24.2 million for the third quarter of 2026, up 14% from the same period of 2025. Growth was driven by continued sales of its new 3870 MR intravenous (IV) infusion pump, according to the firm.

Net income for the quarter (end-September 30) was $6.5 million, up 17% from $5.6 million a year earlier. GAAP diluted earnings per share were $0.51, and non-GAAP diluted earnings per share were $0.55, both up from $0.43 and $0.47, respectively, in the same period last year.

The company’s board of directors also declared a quarterly cash dividend of $0.20 per share, payable November 27, to shareholders of record as of November 13.

For the fourth quarter, iRadimed expects revenue of $25 million to $26.5 million. For the full year, the vendor expects revenue of $91.6 million to $93.1 million.